Context Therapeutics | Investor Presentation Deck | 25 slides · page 3 of 25
The slide uses a structured table-like layout to categorize key business and clinical updates.
Pitch deck · executive_summary · summarize · balanced density
Slide locked Sign in to view
Slide schematic 5/5
list 4/4 title 1/1
Components 5
bullet bullet bullet bullet headline
Tools 2
List presentation slide · 80%
list/bullet: CLDN6 x CD3 bispecific antibody: Uniquely expressed in certain cancers; developing selective antibody; candidate selection Q4 2022, IND Q1 2024
List presentation slide · 80%list/bullet: ONA-XR oral PR antagonist: Novel, potentially first-in-class PR antagonist; Q4 2022 ELONA trial initiation; Q4 2022 preliminary IST data
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.